We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: IBM, United Continental, Lam Research, CSX and Intuitive Surgical
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 18, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM Corp. (IBM - Free Report) , United Continental (UAL - Free Report) , Lam Research (LRCX - Free Report) , CSX Corp. (CSX - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Q1 Earnings Have Liftoff: IBM, UAL, CSX, LRCX and ISRG
After the closing bell Tuesday, a fresh wave of Q1 earnings reports have come out, across a wide swath of sectors. Among the big names posting actuals this afternoon, all came out with exclusively better-than-expected results.
IBM Corp., at first glance, appeared to accomplish what analyst had set out for it: a 5-cent earnings beat to $2.45 per share on $19.1 billion in sales, which surpassed the $18.7 analysts were looking for. These figures represent year-over-year revenue growth for the first time in 5 years, but after-market trading is selling off IBM shares roughly 5%, virtually wiping out the company's gains for all of 2018 so far.
This sell-off may also provide a drag to the Dow index tomorrow morning, which had just finally dug itself out of its hole over the past month. IBM's guidance for full-year 2018 was reaffirmed at $13.80 per share; apparently investors were looking for something a little stronger on this line.
United Continental topped the Zacks consensus earnings estimate by a penny to 50 cents a share, with revenues for the quarter also edging out expectations to $9.03 billion. This marks a 23% upswing in earnings from the year-ago quarter on PRASM metrics up 2.7% in Q1. Full-year guidance have tightened to between $7-8 per share, and the company has beaten estimates on the bottom line for 5 straight quarters.
Lam Research also outperformed estimates, though not by as impressive of margins as some of these companies this afternoon. Headline numbers of $4.79 per share on $2.89 billion in sales also mark the fifth-straight earnings beat, and revenue growth year over year was roughly 33%. Yet late trading is selling the news following a strong regular session, down 2.6% since results were posted. For more on LRCX's earnings, click here.
CSX Corp. easily bettered expectations on the bottom line in its Q1 -- 78 cents per share vs. 66 cents expected, on $2.88 billion in revenues, better than the $2.83 billion expected. This company has also outperformed in the past 5 straight quarters, with a trailing 4-quarter average of over 10%. Late trading is pushing up CSX shares 3.78%.
Finally, Intuitive Surgical posted arguably the most impressive Q1 report of the bunch, with $2.44 per share far outpacing the $1.99 expected, and revenues of $848 million solidly passing the $767 million in the Zacks consensus. Shares in late trading are up 5.6%, putting the MedTech company up near record-high trading territory.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: IBM, United Continental, Lam Research, CSX and Intuitive Surgical
For Immediate Release
Chicago, IL – April 18, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM Corp. (IBM - Free Report) , United Continental (UAL - Free Report) , Lam Research (LRCX - Free Report) , CSX Corp. (CSX - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday’s Analyst Blog:
Q1 Earnings Have Liftoff: IBM, UAL, CSX, LRCX and ISRG
After the closing bell Tuesday, a fresh wave of Q1 earnings reports have come out, across a wide swath of sectors. Among the big names posting actuals this afternoon, all came out with exclusively better-than-expected results.
IBM Corp., at first glance, appeared to accomplish what analyst had set out for it: a 5-cent earnings beat to $2.45 per share on $19.1 billion in sales, which surpassed the $18.7 analysts were looking for. These figures represent year-over-year revenue growth for the first time in 5 years, but after-market trading is selling off IBM shares roughly 5%, virtually wiping out the company's gains for all of 2018 so far.
This sell-off may also provide a drag to the Dow index tomorrow morning, which had just finally dug itself out of its hole over the past month. IBM's guidance for full-year 2018 was reaffirmed at $13.80 per share; apparently investors were looking for something a little stronger on this line.
United Continental topped the Zacks consensus earnings estimate by a penny to 50 cents a share, with revenues for the quarter also edging out expectations to $9.03 billion. This marks a 23% upswing in earnings from the year-ago quarter on PRASM metrics up 2.7% in Q1. Full-year guidance have tightened to between $7-8 per share, and the company has beaten estimates on the bottom line for 5 straight quarters.
Lam Research also outperformed estimates, though not by as impressive of margins as some of these companies this afternoon. Headline numbers of $4.79 per share on $2.89 billion in sales also mark the fifth-straight earnings beat, and revenue growth year over year was roughly 33%. Yet late trading is selling the news following a strong regular session, down 2.6% since results were posted. For more on LRCX's earnings, click here.
CSX Corp. easily bettered expectations on the bottom line in its Q1 -- 78 cents per share vs. 66 cents expected, on $2.88 billion in revenues, better than the $2.83 billion expected. This company has also outperformed in the past 5 straight quarters, with a trailing 4-quarter average of over 10%. Late trading is pushing up CSX shares 3.78%.
Finally, Intuitive Surgical posted arguably the most impressive Q1 report of the bunch, with $2.44 per share far outpacing the $1.99 expected, and revenues of $848 million solidly passing the $767 million in the Zacks consensus. Shares in late trading are up 5.6%, putting the MedTech company up near record-high trading territory.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.